GSK Loses Bid to Block Generic "Flonase"
GSK Loses Bid to Block Generic "Flonase"
GlaxoSmithKline PLC (GSK, London, England, www.gsk.com) reports that a US Federal District Court judge will not grant a preliminary injunction that would have set aside the US Food and Drug Administration’s (Rockville, MD, www.fda.gov) approval of a generic version of GSK’s “Flonase” (fluticasone)
GSK had challenged FDA’s approval in a lawsuit filed Feb. 23, 2006. The company obtained emergency relief from the court that same day in the form of a 10-day temporary restraining order. The order suspended Roxanne Laboratories Inc.’s (Columbus, OH, www.roxane.com) generic product.
Roxanne had received FDA approval for its fluticasone propionate nasal spray, 50 mcg. With the ruling, Roxanne has resumed shipments of the product, said the company in a release. Roxanne is a subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT, www.boehringer-ingelheim.com).
The ruling also cleared the way for the launch of a GSK-authorized generic marketed by Par Pharmaceuticals Companies Inc. (Spring Valley, NY, www.parpharm.com).
GSK says it will not appeal the ruling. “Flonase,” an intranasal corticosteroid spray used to reduce inflammation associated with rhinitis, posted 2005 sales of £656 million ($1.2 billion).
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
